Thursday, December 5, 2019
News on Pathogens and Preparedness
Global Biodefense
No Result
View All Result
  • Featured
  • Pathogens

    Tracing the Ancestral Genome of The Plague

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    Bacillus anthracis concept drawing

    Decontamination of Bacillus Spores from Drinking Water Infrastructure

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    red agar plate with cultured bacteria

    Study Shows Virulence of B. pseudomallei Strain in Aerosol Model

    Turns Out, Bat Influenza Can Give You the Flu

    Turns Out, Bat Influenza Can Give You the Flu

    Crimean-Congo Hemorrhagic Fever

    Crimean Congo Countermeasures: Researchers Investigate CCHFV-RDRp

    Yersinia pestis

    Researchers Optimize Novel Hexaplex PCR Assay for Simultaneous Detection of Anthrax and Plague Pathogens

  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe
  • Featured
  • Pathogens

    Tracing the Ancestral Genome of The Plague

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    Bacillus anthracis concept drawing

    Decontamination of Bacillus Spores from Drinking Water Infrastructure

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    red agar plate with cultured bacteria

    Study Shows Virulence of B. pseudomallei Strain in Aerosol Model

    Turns Out, Bat Influenza Can Give You the Flu

    Turns Out, Bat Influenza Can Give You the Flu

    Crimean-Congo Hemorrhagic Fever

    Crimean Congo Countermeasures: Researchers Investigate CCHFV-RDRp

    Yersinia pestis

    Researchers Optimize Novel Hexaplex PCR Assay for Simultaneous Detection of Anthrax and Plague Pathogens

  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Collaboration Among BARDA, DTRA, USAMRIID and Spero to Advance SPR994

by Global Biodefense
16 Jul 2018
Medical Countermeasure Development

Credit: Shutterstock, modified.

20k
VIEWS

Spero Therapeutics, Inc. today announced that it was awarded funding of $15.7 million, with the potential for up to an additional $28.5 million over 5 years, from the Biomedical Advanced Research and Development Authority (BARDA).

The funding will support the further clinical development of Spero’s oral carbapenem product candidate, SPR994, for the treatment of complicated urinary tract infections (cUTIs) caused by antibiotic resistant Gram-negative bacteria. As part of the inter-agency collaboration with Spero, a series of studies to assess the efficacy of SPR994 in the treatment of infections caused by biodefense threats such as anthrax, plague and melioidosis will be conducted by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

In addition, the Defense Threat Reduction Agency (DTRA) will provide support up to $10 million to fund the nonclinical biodefense aspects of the inter-agency collaboration. The collaboration may also include a clinical trial in pneumonia patients, an indication for which tebipenem, SPR994’s active pharmaceutical ingredient, is currently approved in Japan for pediatric use.

Together, the two agencies will provide up to $54.2 million in total funding for the clinical development and biodefense assessment of SPR994, a portion of which is subject to the exercise of options by BARDA and Spero’s achievement of specified milestones.

“We are honored to be the recipient of an award and to join BARDA and DTRA in this unique inter-agency collaboration. We look forward to advancing SPR994 through clinical development for public and biodefense use as we target public health needs caused by emerging drug-resistant infections,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics. “We believe the funding is a validation of the clinical potential of SPR994 across a broad treatment landscape, and of the ability of a small biotech company to work towards bringing these innovative therapies to patients in collaboration with our partners at BARDA and DTRA.”

The award from BARDA commits $15.7 million of guaranteed initial funding and up to an additional $28.5 million over 5 years if BARDA exercises all of its options under the award.  Additionally, DTRA will commit  $1.25 million of initial support, and up to an additional $8.75 million upon the achievement of specified milestones.

In preclinical studies, SPR994 has shown potent antibiotic activity against Gram-negative bacteria, including E. coli-producing extended-spectrum beta-lactamases (ESBLs) and ESBL-producing Klebsiella pneumoniae, similar to IV-administered ertapenem. Approximately 1,200 subjects have been dosed with tebipenem in clinical and pharmacologic studies conducted by Meiji during its development of tebipenem in Japan.  In addition, available post-marketing outcomes data report the safety and efficacy of tebipenem in 3,540 pediatric patients with pneumonia, otitis media or sinusitis, and these data are consistent with the safety profile of tebipenem as observed in the clinical trial conducted by Meiji.

Tags: AnthraxAwardsBARDABurkholderiaDefense Threat Reduction AgencyMelioidosisUSAMRIIDY. pestis
Previous Post

Rapid Detection of Ricin, Novichok Investigation, Melioidosis in Africa

Next Post

Crab Meat Imported from Venezuela Linked to Multistate Vibrio Outbreak

Related Posts

Klebsiella pneumoniae
Antimicrobial Resistance

Inflammatix Wins BARDA Backing for Diagnostic to Rapidly Distinguish Bacterial from Viral Infections

25 Nov 2019
More People in the U.S. Dying from Antibiotic-Resistant Infections than Previously Estimated
Antimicrobial Resistance

More People in the U.S. Dying from Antibiotic-Resistant Infections than Previously Estimated

13 Nov 2019
Carb-X Funds Techulon’s Rapidly Adaptable Nano Therapeutic in Fight Against Drug Resistant Bacteria
Antimicrobial Resistance

Carb-X Funds Techulon’s Rapidly Adaptable Nano Therapeutic in Fight Against Drug Resistant Bacteria

11 Nov 2019
Diagnosing Sepsis in Minutes: Cytovale Raises $15 Million in Financing
Biodetection

Diagnosing Sepsis in Minutes: Cytovale Raises $15 Million in Financing

9 Nov 2019
Debiopharm Progresses in Their Stand Against Drug-Resistant N. gonorrhoeae
Antimicrobial Resistance

Debiopharm Progresses in Their Stand Against Drug-Resistant N. gonorrhoeae

8 Nov 2019
Genomic Research Viruses
Industry News

Atriva Therapeutics Reports Results of Phase I Clinical Trial for ATR-002 Antiviral

8 Nov 2019
Load More
Next Post
Vibrio parahaemolyticus

Crab Meat Imported from Venezuela Linked to Multistate Vibrio Outbreak

Headlines

  • African Swine Fever Kills More Than 20 Wild Boar in Poland
  • Samoa Measles Outbreak: Death Toll Rises To 53, Mostly Children
  • OPCW Defends Syria Attack Conclusions After Document Leaks
  • Osama bin Laden’s “Anthrax Scientist” Freed by Malaysia
  • New Mobile Lab Born Out of Scientists’ Frustration During Ebola Outbreak

Recommended

  • Highly Sensitive Epigenomic Technology Combats Disease
  • Interview: Ambassador Bonnie Jenkins on 8 years of Combating WMD Terrorism
  • There’s No Such Thing as Just-in-Time Healthcare and Public Health Preparedness
  • Threat Detection in Your Pocket
  • Inflammatix Wins BARDA Backing for Diagnostic to Rapidly Distinguish Bacterial from Viral Infections

Featured Partner

  • About
  • Contact
  • Privacy
  • Subscribe

© 2019 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • Pathogens
  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe

© 2019 Stemar Media Group LLC